Investor News Updates: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Investor News Updates.

Press releases published on May 30, 2026

4 hours ago

Market Logic Network Expands Revenue Operations Systems for Connected Business Growth

Indeterminate EIN Presswire

6 hours ago

HSA for America Urges Americans to Start Open Enrollment Planning Now, Not in November

Indeterminate EIN Presswire

6 hours ago

Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform

Indeterminate EIN Presswire

6 hours ago

Eddy Alexandre Releases 'Trading Options Like a Risk Manager', a Systematic Framework for Independent Traders

Indeterminate Brander

3 hours ago

Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours

Indeterminate GlobeNewswire

3 hours ago

Orion Pharma julkisti ensimmäiset tulokset Faasi 1/2 TEADES-tutkimuksesta ODM-212-molekyylillä (TEAD-estäjä) potilailla, joilla on kiinteitä kasvaimia ja edennyt syöpä

Indeterminate GlobeNewswire

3 hours ago

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Indeterminate GlobeNewswire

3 hours ago

Globale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs

Indeterminate GlobeNewswire

3 hours ago

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

Indeterminate GlobeNewswire

3 hours ago

AI Sector Growth Accelerates Past $26 Billion as Ruvi AI (RUVI) Launches New Features, Proprietary Models, and Ecosystem Upgrades

Indeterminate GlobeNewswire

4 hours ago

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages POET Technologies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – POET

Indeterminate GlobeNewswire

6 hours ago

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Indeterminate GlobeNewswire

7 hours ago

AI Market Cap Crosses $26 Billion as Ruvi AI (RUVI) Unveils Major Platform Upgrade and New Proprietary Technology

Indeterminate GlobeNewswire

8 hours ago

Yanik Guillemette — "Canada Slips Into Recession While Ottawa Bills $200,000 for In-Flight Luxury Meals"

Indeterminate GlobeNewswire

8 hours ago

Yanik Guillemette — « Le Canada entre en récession pendant que nos politiciens mangent pour 200 000 $ en jet privé »

Indeterminate GlobeNewswire

9 hours ago

AI Bots Takes Over XRP Trading as AIX Alpha Launches Its Next‑Gen Automation System

Indeterminate GlobeNewswire

9 hours ago

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

Indeterminate GlobeNewswire

9 hours ago

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1

Indeterminate GlobeNewswire

9 hours ago

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Indeterminate GlobeNewswire

9 hours ago

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Indeterminate GlobeNewswire